EPISODE · Dec 2, 2015 · 9 MIN
Valeant's dose of reality
from FT News in Focus
Valeant was once considered a runaway success story, and one that upended the pharmaceutical sector. A series of crises engulfed the company in recent months, slashing nearly two thirds off its market valuation and forcing the company to tear up its forecasts for 2016. Correspondent David Crow explains. Read the full story at ft.com/valeant.Music: "Brand New Record!" by Steve Combs Hosted on Acast. See acast.com/privacy for more information.
Embed this episode
NOW PLAYING
Valeant's dose of reality
0:00
9:15
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of FT News in Focus?
This episode is 9 minutes long.
When was this FT News in Focus episode published?
This episode was published on December 2, 2015.
Can I download this FT News in Focus episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!